Ryan F. (School of Pharmacy, Queen?s University, Belfast, UK) Donnelly,
RF Donnelly,
Thakur Raghu Raj (School of Pharmacy, Queen?s University, Belfast, UK) Singh,
Desmond I. J. (School of Pharmacy, Queen?s University, Belfast, UK) Morrow,
A. David (School of Pharmacy, Queen?s University, Belfast, UK) Woolfson
e.a.
John Wiley & Sons
e druk, 2012
9780470654897
Microneedle–Mediated Transdermal and Intradermal Drug Delivery
Specificaties
Gebonden, 216 blz.
|
Engels
John Wiley & Sons |
2012
ISBN13: 9780470654897
Rubricering
Verwachte levertijd ongeveer 16 werkdagen
Samenvatting
One of the latest techniques in drug delivery, microneedles are used for administering a wide range of drug substances used to treat various medical conditions. Thorough background information is included providing a history of the field. Various methods used to produce micorneedles are described as well as a snapshot of the future directions within the industry. Written by highly qualified authors, this new text is the only title providing a comprehensive review of microneedle research in the fields of transdermal and intradermal drug delivery.
Specificaties
Inhoudsopgave
Preface, ix
<p>About the Authors, xiii</p>
<p>1 Transdermal Drug Delivery, 1</p>
<p>1.1 Genesis of transdermal drug delivery, 1</p>
<p>1.2 Skin anatomy, 2</p>
<p>1.2.1 The epidermis, 2</p>
<p>1.2.2 The stratum corneum, 4</p>
<p>1.2.3 The dermis, 6</p>
<p>1.2.4 Skin appendages, 6</p>
<p>1.3 Routes to percutaneous drug absorption, 7</p>
<p>1.4 Facilitated transdermal drug delivery, 11</p>
<p>1.4.1 Cryopneumatic and photopneumatic technologies, 12</p>
<p>1.4.2 Sonophoresis (low–frequency ultrasound), 12</p>
<p>1.4.3 Iontophoresis, 13</p>
<p>1.4.4 Electroporation, 14</p>
<p>1.4.5 Jet injection, 14</p>
<p>1.4.6 Microneedles, 15</p>
<p>References, 15</p>
<p>2 Microneedles: Design, Microfabrication and Optimization, 20</p>
<p>2.1 Introduction, 20</p>
<p>2.2 Methods of fabricating microneedles, 21</p>
<p>2.2.1 Microfabrication of silicon microneedles, 22</p>
<p>2.2.2 Microfabrication of metal and other types of MNs, 31</p>
<p>2.2.3 Microfabrication of polymeric microneedles, 34</p>
<p>2.3 Optimization to MN design for transdermal drug delivery, 46</p>
<p>2.4 Conclusion, 49</p>
<p>References, 51</p>
<p>3 Microneedle Applicator Designs for Transdermal Drug Delivery Applications, 57</p>
<p>3.1 Introduction, 57</p>
<p>3.2 Considerations of microneedle applicators designs, 72</p>
<p>3.3 Conclusion, 76</p>
<p>References, 76</p>
<p>4 Transdermal Delivery Applications, 79</p>
<p>4.1 Introduction, 79</p>
<p>4.2 Transdermal drug delivery, 79</p>
<p>4.2.1 Partition co–efficient between 1 and 3, 80</p>
<p>4.2.2 A relatively low melting point, 80</p>
<p>4.2.3 A molecular weight less than 500 Da, 81</p>
<p>4.2.4 Unionized, 81</p>
<p>4.3 Modulation of transdermal penetration using microneedles, 82</p>
<p>4.4 Transdermal delivery using solid microneedles, 83</p>
<p>4.4.1 Transdermal delivery of low molecular weight compounds (RMM < 600 Da) in vitro using solid microneedles, 84</p>
<p>4.4.2 Transdermal delivery of low molecular weight compounds (RMM < 600 Da) in vivo using solid microneedles, 86</p>
<p>4.4.3 Transdermal delivery of high molecular weight compounds (RMM > 600 Da) in vitro using solid microneedles, 88</p>
<p>4.4.4 Transdermal delivery of high molecular weight compounds (RMM > 600 Da) in vivo using solid microneedles, 89</p>
<p>4.5 Transdermal delivery using hollow microneedles, 91</p>
<p>4.5.1 Transdermal delivery of low molecular weight compounds (RMM < 600 Da) in vitro using hollow microneedles, 91</p>
<p>4.5.2 Transdermal delivery of low molecular weight compounds (RMM < 600 Da) in vivo using hollow microneedles, 92</p>
<p>4.5.3 Transdermal delivery of high molecular weight compounds (RMM > 600 Da) in vitro using hollow microneedles, 93</p>
<p>4.5.4 Transdermal delivery of high molecular weight compounds (RMM > 600 Da) in vivo using hollow microneedles, 93</p>
<p>4.6 Transdermal delivery using biodegradable microneedles, 96</p>
<p>4.6.1 Transdermal delivery of low molecular weight compounds in vitro using biodegradable MN, 96</p>
<p>4.6.2 Transdermal delivery of low molecular weight compounds in vivo using biodegradable MN, 98</p>
<p>4.6.3 Transdermal delivery of high molecular weight</p>
<p>compounds in vitro using biodegradable MN, 98</p>
<p>4.6.4 Transdermal delivery of high molecular weight compounds in vivo using biodegradable MN, 100</p>
<p>4.7 Microneedles in combination with other enhancement strategies, 102</p>
<p>4.8 Conclusion, 105</p>
<p>References, 107</p>
<p>5 Microneedle–mediated Intradermal Delivery, 113</p>
<p>5.1 Introduction, 113</p>
<p>5.2 Vaccine delivery, 113</p>
<p>5.2.1 Vaccination, 113</p>
<p>5.3 Intradermal vaccination, 116</p>
<p>5.3.1 Skin structure, 117</p>
<p>5.3.2 Skin immune response, 117</p>
<p>5.3.3 Conventional strategies for intradermal vaccine delivery, 118</p>
<p>5.3.4 Coated microneedles, 120</p>
<p>5.3.5 Poke and Patch approaches, 129</p>
<p>5.3.6 Hollow microneedles, 131</p>
<p>5.3.7 Dissolving/biodegrading polymeric microneedles, 133</p>
<p>5.3.8 Epidermal gene delivery, 135</p>
<p>5.4 Intradermal delivery of photosensitizers for photodynamic therapy, 139</p>
<p>5.4.1 Microneedle–mediated intradermal delivery of 5–aminolevulinic acid and derivatives, 141</p>
<p>5.4.2 Microneedle–mediated intradermal delivery of preformed photosensitizers, 143</p>
<p>5.5 Intradermal delivery of nanoparticles, 144</p>
<p>5.6 Conclusion, 146</p>
<p>References, 147</p>
<p>6 Clinical Application and Safety Studies of Microneedles, 152</p>
<p>6.1 Introduction, 152</p>
<p>6.2 Clinical and safety consideration for MN application, 153</p>
<p>6.2.1 Sensation of pain, 153</p>
<p>6.2.2 Recovery of micropores and possibility of infection following microneedle application, 155</p>
<p>6.2.3 Erythema, 156</p>
<p>6.2.4 Biocompatability and biodegradation of MN material, 157</p>
<p>6.3 Conclusion, 159</p>
<p>References, 160</p>
<p>7 Microneedles: Current Status and Future Perspectives, 164</p>
<p>7.1 Introduction, 164</p>
<p>7.2 Biological fluid sampling devices, 167</p>
<p>7.3 Ocular drug delivery, 172</p>
<p>7.4 Cosmetic applications, 175</p>
<p>7.5 Industrial perspectives, 177</p>
<p>7.6 Hydrogel–forming microneedle arrays, 179</p>
<p>7.7 Moving forwards, 181</p>
<p>7.8 Conclusion, 184</p>
<p>References, 185</p>
<p>Index, 188</p>
<p>About the Authors, xiii</p>
<p>1 Transdermal Drug Delivery, 1</p>
<p>1.1 Genesis of transdermal drug delivery, 1</p>
<p>1.2 Skin anatomy, 2</p>
<p>1.2.1 The epidermis, 2</p>
<p>1.2.2 The stratum corneum, 4</p>
<p>1.2.3 The dermis, 6</p>
<p>1.2.4 Skin appendages, 6</p>
<p>1.3 Routes to percutaneous drug absorption, 7</p>
<p>1.4 Facilitated transdermal drug delivery, 11</p>
<p>1.4.1 Cryopneumatic and photopneumatic technologies, 12</p>
<p>1.4.2 Sonophoresis (low–frequency ultrasound), 12</p>
<p>1.4.3 Iontophoresis, 13</p>
<p>1.4.4 Electroporation, 14</p>
<p>1.4.5 Jet injection, 14</p>
<p>1.4.6 Microneedles, 15</p>
<p>References, 15</p>
<p>2 Microneedles: Design, Microfabrication and Optimization, 20</p>
<p>2.1 Introduction, 20</p>
<p>2.2 Methods of fabricating microneedles, 21</p>
<p>2.2.1 Microfabrication of silicon microneedles, 22</p>
<p>2.2.2 Microfabrication of metal and other types of MNs, 31</p>
<p>2.2.3 Microfabrication of polymeric microneedles, 34</p>
<p>2.3 Optimization to MN design for transdermal drug delivery, 46</p>
<p>2.4 Conclusion, 49</p>
<p>References, 51</p>
<p>3 Microneedle Applicator Designs for Transdermal Drug Delivery Applications, 57</p>
<p>3.1 Introduction, 57</p>
<p>3.2 Considerations of microneedle applicators designs, 72</p>
<p>3.3 Conclusion, 76</p>
<p>References, 76</p>
<p>4 Transdermal Delivery Applications, 79</p>
<p>4.1 Introduction, 79</p>
<p>4.2 Transdermal drug delivery, 79</p>
<p>4.2.1 Partition co–efficient between 1 and 3, 80</p>
<p>4.2.2 A relatively low melting point, 80</p>
<p>4.2.3 A molecular weight less than 500 Da, 81</p>
<p>4.2.4 Unionized, 81</p>
<p>4.3 Modulation of transdermal penetration using microneedles, 82</p>
<p>4.4 Transdermal delivery using solid microneedles, 83</p>
<p>4.4.1 Transdermal delivery of low molecular weight compounds (RMM < 600 Da) in vitro using solid microneedles, 84</p>
<p>4.4.2 Transdermal delivery of low molecular weight compounds (RMM < 600 Da) in vivo using solid microneedles, 86</p>
<p>4.4.3 Transdermal delivery of high molecular weight compounds (RMM > 600 Da) in vitro using solid microneedles, 88</p>
<p>4.4.4 Transdermal delivery of high molecular weight compounds (RMM > 600 Da) in vivo using solid microneedles, 89</p>
<p>4.5 Transdermal delivery using hollow microneedles, 91</p>
<p>4.5.1 Transdermal delivery of low molecular weight compounds (RMM < 600 Da) in vitro using hollow microneedles, 91</p>
<p>4.5.2 Transdermal delivery of low molecular weight compounds (RMM < 600 Da) in vivo using hollow microneedles, 92</p>
<p>4.5.3 Transdermal delivery of high molecular weight compounds (RMM > 600 Da) in vitro using hollow microneedles, 93</p>
<p>4.5.4 Transdermal delivery of high molecular weight compounds (RMM > 600 Da) in vivo using hollow microneedles, 93</p>
<p>4.6 Transdermal delivery using biodegradable microneedles, 96</p>
<p>4.6.1 Transdermal delivery of low molecular weight compounds in vitro using biodegradable MN, 96</p>
<p>4.6.2 Transdermal delivery of low molecular weight compounds in vivo using biodegradable MN, 98</p>
<p>4.6.3 Transdermal delivery of high molecular weight</p>
<p>compounds in vitro using biodegradable MN, 98</p>
<p>4.6.4 Transdermal delivery of high molecular weight compounds in vivo using biodegradable MN, 100</p>
<p>4.7 Microneedles in combination with other enhancement strategies, 102</p>
<p>4.8 Conclusion, 105</p>
<p>References, 107</p>
<p>5 Microneedle–mediated Intradermal Delivery, 113</p>
<p>5.1 Introduction, 113</p>
<p>5.2 Vaccine delivery, 113</p>
<p>5.2.1 Vaccination, 113</p>
<p>5.3 Intradermal vaccination, 116</p>
<p>5.3.1 Skin structure, 117</p>
<p>5.3.2 Skin immune response, 117</p>
<p>5.3.3 Conventional strategies for intradermal vaccine delivery, 118</p>
<p>5.3.4 Coated microneedles, 120</p>
<p>5.3.5 Poke and Patch approaches, 129</p>
<p>5.3.6 Hollow microneedles, 131</p>
<p>5.3.7 Dissolving/biodegrading polymeric microneedles, 133</p>
<p>5.3.8 Epidermal gene delivery, 135</p>
<p>5.4 Intradermal delivery of photosensitizers for photodynamic therapy, 139</p>
<p>5.4.1 Microneedle–mediated intradermal delivery of 5–aminolevulinic acid and derivatives, 141</p>
<p>5.4.2 Microneedle–mediated intradermal delivery of preformed photosensitizers, 143</p>
<p>5.5 Intradermal delivery of nanoparticles, 144</p>
<p>5.6 Conclusion, 146</p>
<p>References, 147</p>
<p>6 Clinical Application and Safety Studies of Microneedles, 152</p>
<p>6.1 Introduction, 152</p>
<p>6.2 Clinical and safety consideration for MN application, 153</p>
<p>6.2.1 Sensation of pain, 153</p>
<p>6.2.2 Recovery of micropores and possibility of infection following microneedle application, 155</p>
<p>6.2.3 Erythema, 156</p>
<p>6.2.4 Biocompatability and biodegradation of MN material, 157</p>
<p>6.3 Conclusion, 159</p>
<p>References, 160</p>
<p>7 Microneedles: Current Status and Future Perspectives, 164</p>
<p>7.1 Introduction, 164</p>
<p>7.2 Biological fluid sampling devices, 167</p>
<p>7.3 Ocular drug delivery, 172</p>
<p>7.4 Cosmetic applications, 175</p>
<p>7.5 Industrial perspectives, 177</p>
<p>7.6 Hydrogel–forming microneedle arrays, 179</p>
<p>7.7 Moving forwards, 181</p>
<p>7.8 Conclusion, 184</p>
<p>References, 185</p>
<p>Index, 188</p>